Case Report: Intervention of radiotherapy improves the prognosis of rectal squamous cell carcinoma with high PD-L1 expression and enable patients to obtain NED status.
PD-L1
chemotherapy
immunotherapy
radiotherapy
rectal squamous cell carcinoma
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
06
06
2023
accepted:
28
06
2023
medline:
1
8
2023
pubmed:
31
7
2023
entrez:
31
7
2023
Statut:
epublish
Résumé
Rectal squamous cell carcinoma (RSCC) is a rare malignancy of the rectal tumor. Due to its extremely low incidence, there is still a lack of high-level treatment evidence and clinical consensus on this disease. In this article, we report a treatment process of RSCC with high PD-L1 expression. Firstly, this patient received 2 cycles of Pembrolizumab immunotherapy, but the efficacy was less sanguine. Subsequently, 4 cycles of mFOLFOX6 chemotherapy were synchronously performed on the basis of the initial regimen. Although partial remission was achieved in the lymph nodes thereafter, the changes in the primary lesions were still not significant. After that, the patient received radiotherapy, and followed by 6 cycles of PC (Albumin-binding Paclitaxel and Nedaplatin) regimen chemotherapy combined with Pembrolizumab. Eventually, the patient achieved no evidence of disease (NED) status, and no signs of recurrence or metastasis were found after 12 months of follow-up. This is the first report of a RSCC patient with high PD-L1 expression achieving a complete response. Looking back over the whole treatment process of this patient, we found that the participation of radiotherapy was the inflection point of prominent efficacy, which may provide a new idea for the selection of comprehensive treatment strategies for patients with RSCC.
Sections du résumé
Background
Rectal squamous cell carcinoma (RSCC) is a rare malignancy of the rectal tumor. Due to its extremely low incidence, there is still a lack of high-level treatment evidence and clinical consensus on this disease.
Case report
In this article, we report a treatment process of RSCC with high PD-L1 expression. Firstly, this patient received 2 cycles of Pembrolizumab immunotherapy, but the efficacy was less sanguine. Subsequently, 4 cycles of mFOLFOX6 chemotherapy were synchronously performed on the basis of the initial regimen. Although partial remission was achieved in the lymph nodes thereafter, the changes in the primary lesions were still not significant. After that, the patient received radiotherapy, and followed by 6 cycles of PC (Albumin-binding Paclitaxel and Nedaplatin) regimen chemotherapy combined with Pembrolizumab. Eventually, the patient achieved no evidence of disease (NED) status, and no signs of recurrence or metastasis were found after 12 months of follow-up.
Conclusion
This is the first report of a RSCC patient with high PD-L1 expression achieving a complete response. Looking back over the whole treatment process of this patient, we found that the participation of radiotherapy was the inflection point of prominent efficacy, which may provide a new idea for the selection of comprehensive treatment strategies for patients with RSCC.
Identifiants
pubmed: 37520582
doi: 10.3389/fimmu.2023.1235697
pmc: PMC10382127
doi:
Substances chimiques
B7-H1 Antigen
0
Types de publication
Case Reports
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1235697Informations de copyright
Copyright © 2023 Qu, Xiao, Xiao, Gao, Wang, Wang, Gao, Wu and Liu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Oncol. 2012 Aug 07;2:88
pubmed: 22891162
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Ann Palliat Med. 2020 Jul;9(4):2393-2399
pubmed: 32762232
Cancer Lett. 2019 Jun 28;452:66-70
pubmed: 30902563
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
J Immunol. 2012 Jul 15;189(2):558-66
pubmed: 22685313
Curr Drug Targets. 2020;21(14):1463-1475
pubmed: 32160846
J Immunol. 2008 Sep 1;181(5):3099-107
pubmed: 18713980
PLoS One. 2017 Dec 28;12(12):e0189848
pubmed: 29284010
Int J Colorectal Dis. 2015 Jan;30(1):127-30
pubmed: 25392258
Cancer Med. 2016 Dec;5(12):3394-3402
pubmed: 27781400
Nature. 2017 Dec 7;552(7683):116-120
pubmed: 29186113
World J Gastrointest Surg. 2016 Mar 27;8(3):252-65
pubmed: 27022453
Eur J Surg Oncol. 2020 Jun;46(6):1111-1117
pubmed: 32201124
World J Gastroenterol. 2009 Sep 21;15(35):4380-6
pubmed: 19764088
J Clin Oncol. 2020 Dec 10;38(35):4138-4148
pubmed: 33026938
ESMO Open. 2021 Aug;6(4):100180
pubmed: 34111760
Cancer Immunol Res. 2015 May;3(5):436-43
pubmed: 25941355
Rev Esp Enferm Dig. 2016 Dec;108(12):826-835
pubmed: 26911877
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Cancer. 2018 Oct 15;124(20):3990-3999
pubmed: 29975400
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
Int J Surg Case Rep. 2015;7C:127-9
pubmed: 25465645
Nat Commun. 2017 Nov 24;8(1):1751
pubmed: 29170499
J Gastrointest Oncol. 2020 Apr;11(2):242-249
pubmed: 32399265
J Gastroenterol. 2023 Feb;58(2):125-134
pubmed: 36357817
Nat Cancer. 2020 Jul;1(7):681-691
pubmed: 35122038